Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 - PubMed (original) (raw)
doi: 10.1016/s1074-7613(00)00070-4.
R Lesley, B Blom, J C Timans, Y Xu, B Hunte, F Vega, N Yu, J Wang, K Singh, F Zonin, E Vaisberg, T Churakova, M Liu, D Gorman, J Wagner, S Zurawski, Y Liu, J S Abrams, K W Moore, D Rennick, R de Waal-Malefyt, C Hannum, J F Bazan, R A Kastelein
Affiliations
- PMID: 11114383
- DOI: 10.1016/s1074-7613(00)00070-4
Free article
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
B Oppmann et al. Immunity. 2000 Nov.
Free article
Abstract
A novel sequence discovered in a computational screen appears distantly related to the p35 subunit of IL-12. This factor, which we term p19, shows no biological activity by itself; instead, it combines with the p40 subunit of IL-12 to form a novel, biologically active, composite cytokine, which we term IL-23. Activated dendritic cells secrete detectable levels of this complex. IL-23 binds to IL-12R beta 1 but fails to engage IL-12R beta 2; nonetheless, IL-23 activates Stat4 in PHA blast T cells. IL-23 induces strong proliferation of mouse memory (CD4(+)CD45Rb(low)) T cells, a unique activity of IL-23 as IL-12 has no effect on this cell population. Similar to IL-12, human IL-23 stimulates IFN-gamma production and proliferation in PHA blast T cells, as well as in CD45RO (memory) T cells.
Similar articles
- The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases.
Hölscher C. Hölscher C. Med Microbiol Immunol. 2004 Feb;193(1):1-17. doi: 10.1007/s00430-003-0186-x. Epub 2003 Jun 27. Med Microbiol Immunol. 2004. PMID: 12836019 Review. - Regulation of virus-induced IL-12 and IL-23 expression in human macrophages.
Pirhonen J, Matikainen S, Julkunen I. Pirhonen J, et al. J Immunol. 2002 Nov 15;169(10):5673-8. doi: 10.4049/jimmunol.169.10.5673. J Immunol. 2002. PMID: 12421946 - Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells.
Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D. Sheibanie AF, et al. FASEB J. 2004 Aug;18(11):1318-20. doi: 10.1096/fj.03-1367fje. Epub 2004 Jun 4. FASEB J. 2004. PMID: 15180965 - IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available.
Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, Ghilardi N, deSauvage F, Cooper AM. Khader SA, et al. J Immunol. 2005 Jul 15;175(2):788-95. doi: 10.4049/jimmunol.175.2.788. J Immunol. 2005. PMID: 16002675 - A unique role for IL-23 in promoting cellular immunity.
Lankford CS, Frucht DM. Lankford CS, et al. J Leukoc Biol. 2003 Jan;73(1):49-56. doi: 10.1189/jlb.0602326. J Leukoc Biol. 2003. PMID: 12525561 Review.
Cited by
- Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells.
Ohara D, Takeuchi Y, Hirota K. Ohara D, et al. Cell Mol Immunol. 2024 Nov;21(11):1183-1200. doi: 10.1038/s41423-024-01218-x. Epub 2024 Oct 8. Cell Mol Immunol. 2024. PMID: 39379604 Free PMC article. Review. - Human IL-22 receptor-targeted small protein antagonist suppress murine DSS-induced colitis.
Kuchař M, Sloupenská K, Rašková Kafková L, Groza Y, Škarda J, Kosztyu P, Hlavničková M, Mierzwicka JM, Osička R, Petroková H, Walimbwa SI, Bharadwaj S, Černý J, Raška M, Malý P. Kuchař M, et al. Cell Commun Signal. 2024 Oct 1;22(1):469. doi: 10.1186/s12964-024-01846-w. Cell Commun Signal. 2024. PMID: 39354587 Free PMC article. - Microbiome- and Host Inflammasome-Targeting Inhibitor Nanoligomers Are Therapeutic in the Murine Colitis Model.
Sharma S, Gilberto VS, Levens CL, Chatterjee A, Kuhn KA, Nagpal P. Sharma S, et al. ACS Pharmacol Transl Sci. 2024 Aug 30;7(9):2677-2693. doi: 10.1021/acsptsci.4c00102. eCollection 2024 Sep 13. ACS Pharmacol Transl Sci. 2024. PMID: 39296260 - Emerging immunologic approaches as cancer anti-angiogenic therapies.
Azimi M, Manavi MS, Afshinpour M, Khorram R, Vafadar R, Rezaei-Tazangi F, Arabzadeh D, Arabzadeh S, Ebrahimi N, Aref AR. Azimi M, et al. Clin Transl Oncol. 2024 Sep 18. doi: 10.1007/s12094-024-03667-2. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39294514 Review. - Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience.
Marcelli L, Belcastro A, Talamonti M, Paganini C, Fico A, Savastano L, Di Raimondo C, Vellucci L, Bianchi L, Galluzzo M. Marcelli L, et al. J Clin Med. 2024 Aug 31;13(17):5175. doi: 10.3390/jcm13175175. J Clin Med. 2024. PMID: 39274388 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous